Serge Hardy

PTPN1 and PTPN2 cooperatively set interferon responsiveness thresholds that govern cancer immune evasion

Immune evasion by cancer cells remains a major barrier to the success of immune checkpoint blockade (ICB). In recent years, Protein tyrosine phosphatase non-receptor type 2 (PTPN2) has emerged as a promising and druggable target for cancer immunotherapy. Small-molecule agents cur...